Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized Phase 3 Study to Evaluate 9MW2821 vs Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Urothelial Cancer Who Have Previously Received PD-(L)1 Inhibitor and Platinum-containing Chemotherapy

NCT06196736 is registered in ClinicalTrials.gov with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor.

NCT NCT06196736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06196736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized Phase 3 Study to Evaluate 9MW2821 vs Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Urothelial Cancer Who Have Previously Received PD-(L)1 Inhibitor and Platinum-containing Chemotherapy
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
December 29, 2023
Completion date
July 31, 2027
Enrollment
432 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced urothelial carcinoma